Is CXW a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Reactivating idle beds, with revenue (ttm) at ~$2.48B. The bear case rests on the concentration risk is unusually direct: roughly half of revenue comes from two federal agencies whose budgets and enforcement posture change with administrations, and government contracts here typically run in short terms with termination-for-convenience provisions. Analysts covering it are spread from $36.00 to $45.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The concentration risk is unusually direct: roughly half of revenue comes from two federal agencies whose budgets and enforcement posture change with administrations, and government contracts here typically run in short terms with termination-for-convenience provisions. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $36.00, +7.1% from the $33.60 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Reactivating idle beds. The clearest earnings lever is turning facilities that were sitting empty back into contracted, occupied capacity. The most optimistic analyst target on CXW is $45.00, +33.9% from the $33.60 price. That figure is only reachable if this thesis works close to its best case.

The concentration risk is unusually direct: roughly half of revenue comes from two federal agencies whose budgets and enforcement posture change with administrations, and government contracts here typically run in short terms with termination-for-convenience provisions. A 2021 executive order directing the Justice Department not to renew private prison contracts removed CoreCivic's Bureau of Prisons business, a worked example of how fast policy can subtract revenue, and several states including California, Illinois, New Jersey and Washington restrict private detention outright. ESG exclusion is a structural overhang rather than a headline problem: numerous funds screen the sector out and several large banks stopped lending to private prison operators after 2019, which narrows both the shareholder base and financing options, and was part of the backdrop to the REIT exit. Selling facilities to DHS raises cash but leaves CoreCivic managing beds it no longer owns, which lowers margins and shortens the tie between the company and the assets. Staffing costs, occupancy swings, litigation and reputational scrutiny round out the operating risks. The most pessimistic published target is $36.00, +7.1% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

Owner and operator of correctional and detention facilities under government contract, with ICE and the US Marshals supplying most of its revenue.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Reactivating idle beds) stalling in the reported numbers rather than in the narrative, the risk above (the concentration risk is unusually direct: roughly half of revenue comes from two federal agencies whose budgets and enforcement posture change with administrations, and government contracts here typically run in short terms with termination-for-convenience provisions) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

CoreCivic owns, leases and operates correctional, detention and residential reentry facilities under contract with government agencies. Its largest customers are US Immigration and Customs Enforcement and the US Marshals Service, followed by state departments of correction and local governments. It is generally paid a per diem rate for each resident housed each day, so occupancy and contracted bed counts drive results. In April 2026 it also acquired a correctional pharmacy business.

No. CoreCivic operated as a real estate investment trust until it revoked that election effective January 1, 2021, and it has been taxed as an ordinary C corporation since. The change let it retain cash flow to reduce debt rather than distribute it, at the cost of paying corporate income tax. It still reports funds from operations, a metric carried over from the REIT years, which can confuse comparisons.

CoreCivic suspended its quarterly dividend in 2020 while it reviewed its corporate structure and capital allocation, and it has not reinstated one. Capital has gone to debt reduction and share repurchases instead. The board expanded the buyback authorization by $500 million in 2026 to $1.2 billion in total, with roughly $756 million still available after the facility sales to the Department of Homeland Security.